PATENT USSN 08/974,584 015389-002950US 018/206p2

## CLAIM AMENDMENTS

1 to 118. CANCELLED

119. (Currently amended) A recombinant or synthetic polynucleotide encoding a protein that comprises an amino acid sequence at least 60% identical to SEQ. ID NO:118, and that comprises each of the following structures:

- Ŧ<del>ŗp-R<sub>1</sub>-X<sub>2-</sub>R<sub>1</sub>-R<sub>1-</sub>R<sub>2-</sub>X-Pho-Pho-Tyr-X-Thr-Glu-X<sub>8-0</sub>-R<sub>3</sub>-R<sub>3</sub>-A<del>rg-</del>R<sub>4</sub>-X<sub>4</sub>-<del>Trp (SEQ. ID</del></del> NOS:16 and 17) X<sub>s</sub>-Arg-X<sub>2</sub>-Pro-Lys-X<sub>3</sub> (SEQ. ID NO:139) b) a)
- X-Arg-X-IIe-X (SEQ. ID NO:143) 6) 회
- $X_4$ -Phe- $X_3$ -Asp- $X_4$ -Tyr-Asp- $X_2$  (SEQ, ID NO:144) Tyr- $X_4$ -Gly- $X_2$ -Gln-Gly- $X_3$ -Ser- $X_8$  (SEQ, ID NO:146)  $X_6$ -Asp-Asp-X-Leu- $X_3$  (SEQ, ID NO:147) <u>and</u> <del>d)</del> <u>c)</u> <del>0)</del> <u>d)</u>
- f) e)
  - either: Trp-R1-X7-R1-R1-R2-X-Phe-Phe-Tyr-X-Thr-Glu-X8-R3-R3-Arg-R4-X2-Trp (SEQ. ID NO:16), or: Trp-R<sub>1</sub>-X<sub>2</sub>-R<sub>1</sub>-R<sub>1</sub>-R<sub>2</sub>-X-Phe-Phe-Tyr-X-Thr-Glu-X<sub>0</sub>-R<sub>2</sub>-R<sub>2</sub>-Arg-R<sub>4</sub>-X<sub>2</sub>-Trp (SEQ. ID NO:17);

wherein R1 is Leu or Ile; R2 is Gln or Arg; R3 is Phe or Tyr; R4 is Lys or His, and Xn represents the number n of consecutive unspecified amino acids;

and wherein the protein has telomerase catalytic activity when complexed with a telomerase RNA component.

- 120. (Previously presented) The polynucleotide of claim 119, comprising the structure Trp-Leu-X-Tyr- $X_2$ -h-h-X-h-h-X-p-Phe-Phe-Tyr-X-Thr-Glu-X-p- $X_3$ -p- $X_3$ -Tyr-X-Arg-Lys- $X_2$ -Trp (SEQ. ID NO:116); wherein h is a hydrophobic amino acid selected from Ala, Leu, Ile, Val, Pro, Phe, Trp, and Met; and p is a polar amino acid selected from Gly, Ser, Thr, Tyr, Cys, Asn and Gln.
- 121. (Currently amended) The polynucleotide of claim 119, where structure e) 1 further comprises Arg-Lys-X<sub>2</sub>-Trp-X<sub>2</sub>-Leu (SEQ ID NO:477).
- 122. (Currently amended) The polynucleotide of claim 119, where structure b) a) comprises h-Arg-h-X-Pro-Lys, wherein h is a hydrophobic amino acid selected from Ala, Leu, Ile, Val, Pro, Phe, Trp, and Met (SEQ ID NO:473).
- 123. (Currently amended) The polynucleotide of claim 119, where structure e) b) comprises Arg-X-lie-Pro-Lys (SEQ ID NO:478).

PAGE 8/17 \* RCVD AT 1/30/2004 6:36:41 PM [Eastern Standard Time] \* SVR:USPTO-EFXRF-1/3 \* DNIS:8729306 \* CSID:46504738654 \* DURATION (mm-5s):04-00

PATENT USSN 08/974,584 015389-002950US 018/206p2

- 124. (Currently amended) The polynucleotide of claim 119, where structure e) d) comprises Gly-lie-Pro-Gln-Gly-Ser (SEQ ID NO:370).
- 125. (Currently amended) The polynucleotide of claim 119, where structure \$\text{9}\ \overline{\omega}\$ comprises Leu-Leu-Leu-Arg-Leu-X-Asp-Asp-Phe-Leu (SEQ ID NO:479).
- 126. (Currently amended) The polynucleotide of claim 119, comprising at least 10 consecutive amino acids of SEQ. ID NO:123 SEQ. ID NO:118.
- 127. (Withdrawn) A method for increasing proliferative capacity of a cell of a vertebrate species, comprising expressing the polynucleotide of claim 119 in the cell.